Status:
RECRUITING
Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
Lead Sponsor:
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Conditions:
Insomnia Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
Eligibility Criteria
Inclusion
- Males and females, aged ≥ 18 to \< 65 years.
- Meet the clinical diagnostic criteria for insomnia disorder as defined in ICSD-3 criteria.
- sTSO ≥ 30 min for at least 3 nights per week and/or sWASO ≥ 60 min for at least 3 nights per week within 4 weeks prior to screening.
- Able to recognize 26 English letters and MMSE score indicats no cognitive impairment.
- During the run-in period and on Day 1 of the treatment period, sTSO ≥ 30 min for at least 3 nights in the last 7 sleep diaries and/or sWASO ≥ 60 min for at least 3 nights out of 7 nights as confirmed by the sleep diary prior to PSG monitoring.
- PSG results for 2 consecutive nights during the run-in period should meet the following conditions:
- The mean LPS ≥ 30 min for 2 nights and ≥ 20 min for any one night; And/or the mean WASO ≥ 60 min for 2 nights, and ≥ 45 min either night.
- The mean SE ≤ 85% for 2nights, with the SE ≤ 87.5% for both nights .
- ISI score ≥ 15 at screening and on Day 1 of the treatment period .
- Have a bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m., and stay in bed for 6.5 to 9 hours for at least 5 nights in the last 7 sleep diaries as confirmed by the sleep diary prior to PSG monitoring during the run-in period and on Day 1 of the treatment period.
- Reproductive-age male and female participants must agree to use effective contraceptive measures from the screening visit through at least 30 days after the last dose of double-blind study treatment, and must not be planning to become pregnant or donate sperm/eggs during this period.
- Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Informed Consent Form, have good compliance during participation in the study, and are willing to attend the visits.
Exclusion
- Hypersensitivity to YZJ-1139 tablets or zolpidem or to their excipients.
- Have serious endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, autoimmune diseases, impaired respiratory function or other related diseases, or have other medical history that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
- Have insomnia disorder due to other causes such as chronic pain, headache, eczema, neurodermatitis, allergic rhinitis, and serious dermatitis (difficulty sleeping due to physical reasons, difficulty falling asleep due to medical reasons).
- Current or previous history of psychiatric or neurological disease such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
- Previous history of sleep-related respiratory disorders including obstructive sleep apnea (with or without continuous positive airway pressure \[CPAP\] therapy), periodic limb movement disorder, myasthenia gravis, restless legs syndrome, circadian rhythm sleep disturbances, narcolepsy or other sleep disorders: subjects with restless legs syndrome which is diagnosed by relevant diagnostic and treatment guidelines should be excluded. Those who have been cured of the above diseases can be enrolled.
- Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
- Have nocturia increased caused by urinary tract infection, urinary tract injury or prostatic disorder.
- Hyperthyroidism.
- History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor) within the past 6 months.
- Regular daily consumption of excessive tea and coffee drinks (defined as consumption of \> 4 cups of caffeinated beverages or \> 400 mg of caffeine per day), or daily habituation to drinking caffeinated beverages beyond 18:00.
Key Trial Info
Start Date :
March 25 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06975514
Start Date
March 25 2025
End Date
September 1 2025
Last Update
July 15 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, China
2
ChengDu Second People's Hospital
Chengdu, China
3
ChongQing Traditional Chinese Medicine Hospital
Chongqing, China
4
Deyang People's Hospital
Deyang, China